Please assess the completion status of the following clinical trial:

Trial Title: Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Males and females, ≥ 18 years of age~* HCV Genotype 1b who previously failed treatment with peginterferon alfa and ribavirin, classified as previous null or partial responders based on previous therapy, OR intolerant or ineligible to P/R due to neutropenia, anemia, depression or thrombocytopenia with fibrosis/cirrhosis, OR treatment naive~* HCV RNA ≥ 10,000 IU/mL~* Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg)~* Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)~Exclusion Criteria:~* Prior treatment of HCV with HCV direct acting antiviral (DAA)~* Evidence of a medical condition contributing to chronic liver disease other than HCV~* Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy~* Diagnosed or suspected hepatocellular carcinoma or other malignancies~* Uncontrolled diabetes or hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Null or Partial Responder to P/R (ASV + DCV) (Type: EXPERIMENTAL): Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks
- Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV) (Type: EXPERIMENTAL): Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks
- Arm 3: Treatment naive (ASV + DCV) (Type: EXPERIMENTAL): \[Subjects will receive ASV + DCV for 24 weeks\] followed by ASV + DCV for 24 weeks in protocol AI444026\]~Subjects meeting prespecified rescue criteria in the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg/1200 mg (total daily dose) tablet by mouth for 24 or 48 weeks
- Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week (Type: EXPERIMENTAL): Subjects meeting prespecified rescue criteria in the null or partial responder cohort or active arm of the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg / 1200 mg (total daily dose) Tablet by mouth, for 24 or 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete